Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 11/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 6/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 6/20 | 0.35 |
| ▸ | BMPR1B | O00238 | 5/20 | 0.35 |
| ▸ | BMPR1A | P36894 | 5/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769027 | 0.85 | CYP11B2 (0.41) | CYP11B2CYP11B1ACVRL1ACVR1BMPR1B | |
| SCHEMBL769604 | 0.81 | CYP11B1 (0.40) | CYP11B2CYP11B1ACVRL1ACVR1BMPR1B | |
| SCHEMBL777266 | 0.80 | ACVRL1 (0.56) | CYP11B2CYP11B1ACVRL1ACVR1BMPR1B | |
| SCHEMBL15869740 | 0.80 | CYP11B1 (0.39) | CYP11B2CYP11B1ACVRL1ACVR1BMPR1B | |
| SCHEMBL768785 | 0.79 | PIK3C3 (0.37) | CYP11B2CYP11B1ACVRL1ACVR1BMPR1B | |
| SCHEMBL15869738 | 0.78 | CYP11B2 (0.42) | CYP11B2CYP11B1ACVRL1ACVR1BMPR1B | |
| SCHEMBL769387 | 0.78 | LMNA (0.41) | CYP11B2CYP11B1ACVRL1ACVR1BMPR1B | |
| SCHEMBL768345 | 0.78 | MEN1 (0.40) | CYP11B2CYP11B1ACVRL1ACVR1BMPR1B | |
| SCHEMBL15869737 | 0.77 | CYP11B1 (0.38) | CYP11B2CYP11B1ACVRL1ACVR1BMPR1B | |
| SCHEMBL769240 | 0.77 | CYP11B1 (0.41) | CYP11B2CYP11B1ACVRL1ACVR1BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275175-A1 | ORGANIC COMPOUNDS | CYP11B2, CYP11B1, SLCO1B1 | CYP11B2 1/4885CYP11B1 2/4885ACVRL1 3179/4885 |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | CYP11B1, HSD11B1, CYP11B2 | CYP11B2 3/4885CYP11B1 1/4885ACVRL1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.